Immunotherapy in Allergic Skin Disease
Allergic skin diseases, such as atopic dermatitis (AD) and urticaria are common diseases with increasing incidence in recent decades that are responsible for a serious burden on patients and their families, highlighting the need for devising effective therapeutic and preventive strategies. During the past few years, there have been significant advances in our understanding of the cellular and immunologic mechanisms underlying allergic skin diseases. Allergen-specific immunotherapy (SIT) that involves the administration of increasing concentrations of crude allergen extracts over a period of time, in an attempt to switch the indi- vidual’s allergic response to that of a non-allergic individual, is widely recognized as an effective treatment in asthma and allergic rhinitis, while its efficacy in most common allergic skin diseases, AD has been a matter of debate for a long time??Some novel immunotherapeutic approaches including monoclonal antibodies, CpG DNA, peptides, and recombinant allergen vaccines has significantly increased our treatment options. In this review, we provide some of the recent advances in our understanding of the immunotherapy in allergic skin disease AD.
KeywordsAtopic Dermatitis Allergic Skin Disease
Unable to display preview. Download preview PDF.
- Abramson, M.J., Puy, R.M., Weiner, J.M. (2003). Allergen immunotherapy for asthma. Cochrane Database Syst Rev, (4), CD001186.Google Scholar
- Bousquet, J., Demoly, P., Michel, F. (2001). Specific immunotherapy in rhinitis and asthma. J Allergy Clin Immunol, 87(1), 38–42.Google Scholar
- Calderon, M.A., Alves, B., Jacobson, M. (2007). Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev, 24 (1), CD001936.Google Scholar
- Cosmi, L., Santarlasci, V., Angeli, R., et al. (2006). Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma-and interleukin-10-production. Clin Exp Allergy, 36(3), 261–272.PubMedCrossRefGoogle Scholar
- Durham, S.R., Ying, S., Varney, V.A., et al. (1996). Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol, 97(6), 1356–1365.PubMedCrossRefGoogle Scholar
- Gardner, L.M., Thien, F.C., Douglass, J.A., et al. (2004c). Induction of T “regulatory” cells by standardized house dust mite immunotherapy: An increase in CD4+ CD25+ interleukin-10+ T-cells expressing peripheral tissue trafficking markers. Clin Exp Allergy, 34(8), 1209–1219.PubMedCrossRefGoogle Scholar
- Mastrandrea, F., Serio, G., Minelli, M., et al. (2000). Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr), 28(2), 54–62.Google Scholar
- Mothes, N., Heinzkill, M., Drachenberg, K.J., et al. (2003). Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: Reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy, 33 (9), 1198–1208.PubMedCrossRefGoogle Scholar